The Zhitong Finance App learned that two experimental drugs used to treat a rare endocrine cancer and a fatal lung disease were successful in phase III clinical studies, injecting momentum into the pharmaceutical company's new product pipeline. Boosted by this news, as of press release, Bristol-Myers Squibb's US stocks rose nearly 4% before the market on Monday.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.